Luxembourg Cancer Institute Launches Precision Oncology Study

Oct 29, 2018

|

NEW YORK (GenomeWeb) — Luxembourg's Institut National du Cancer (INC) announced today that it has begun an initiative to evaluate the use of molecular diagnostics in cancer treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct

14

Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct

15

Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct

29

Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Menu

Luxembourg Cancer Institute Launches Precision Oncology Study

To read the full story....

Breaking News

Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST

BMS's Opdivo Prolongs Disease-Free Survival as Adjuvant Treatment for Patients With Bladder Cancer

Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

How to Train Your DRAGEN for Pathology Informatics

What's Popular?

Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

Roche's Ipatasertib, Anti-Androgen Therapy Improves Outcomes in Prostate Cancer With PTEN Loss

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

HPV, p16 May Offer Different Prognostic Clues in Oropharyngeal Cancer, ESMO Data Reveals

Sponsorships